Novo Nordisk's Rare Disease Breakthrough Fails to Lift Oversold Shares

Novo Nordisk reports positive Phase 3 results for sickle cell drug etavopivat, but shares remain under pressure from intense GLP-1 competition and shifting market dynamics.

Novo Nordisk's stock remains deeply oversold, trading more than 50% below its 52-week high, despite the company announcing a clear clinical win. The Danish pharmaceutical giant reported positive Phase 3 results for etavopivat, an oral treatment for sickle cell disease, marking a significant step in its strategic push beyond its core diabetes and obesity franchises. Yet, this news was insufficient to reverse the share price decline on Monday, highlighting the intense competitive pressures facing its blockbuster weight-loss drugs.

The HIBISCUS trial, involving 385 patients aged twelve and older, successfully met both co-primary endpoints. Treatment with etavopivat reduced the annual rate of painful vaso-occlusive crises by 27% compared to a placebo. Perhaps more striking was the hemoglobin response: nearly 49% of patients receiving the drug achieved an increase of more than 1 g/dL after 24 weeks, versus just 7.2% in the placebo group. The safety profile remained consistent with earlier study data, presenting a clinically robust outcome.

This drug candidate represents the first potential product from Novo Nordisk's $1.1 billion acquisition of Forma Therapeutics in 2022. The company plans to submit its first regulatory applications for etavopivat in the second half of 2026. The therapy already holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, with Orphan status also granted in Europe. Market analysts at GlobalData project the drug could achieve annual sales of $174 million by 2032.

The development comes as the competitive landscape for sickle cell therapies shifts. Pfizer withdrew its rival drug, voxelotor, from the market in 2024, while other treatments face challenges. For Novo Nordisk, success in this rare disease area—which affects an estimated eight million people globally—is a deliberate move to diversify away from the increasingly crowded GLP-1 market.

That core market is showing signs of strain. Recent U.S. prescription data reveals a notable shift within Novo's own portfolio: the tablet form of its obesity drug Wegovy now accounts for 29% of all Wegovy prescriptions, indicating a strong trend away from injectables. In a single reference week, the oral Wegovy variant recorded approximately 3,071 prescriptions. However, Eli Lilly's newly launched competitor, Foundayo, garnered 1,390 scripts in the same period, demonstrating the rapid encroachment of rival products.

Amid these dynamics, Novo Nordisk continues to execute a substantial share buyback program. The ongoing initiative is valued at 15 billion Danish kroner. Since mid-April, the company has repurchased 1.25 million shares for about 313 million DKK. Cumulatively, it now holds 12.26 million of its own B-shares, equivalent to 0.7% of its share capital. Other figures indicate that since February, buybacks under this program have totaled roughly 12.3 million B-shares for a value of approximately 3.15 billion DKK.

Technically, the stock appears oversold. With a Relative Strength Index (RSI) reading under 25 and a price hovering around 34.56 euros—still about 51% below its June 2025 peak—the chart suggests significant selling pressure has taken hold. The positive etavopivat data alone could not catalyze a turnaround in sentiment. The market's focus is now fixed on whether upcoming regulatory filings for the sickle cell drug and the trajectory of Wegovy's prescription trends in the latter half of 2026 can finally trigger a meaningful re-rating of the shares.